VRDN241220P25000
- 0.00
- 0.000.00%
Viridian Therapeutics Newsroom
Needham Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38
Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target
TD Cowen Initiates Viridian Therapeutics(VRDN.US) With Buy Rating
Viridian Therapeutics: Buy Rating Due to Promising TED Therapy and Market Potential
Viridian Therapeutics Analyst Ratings
H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $34
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $44
Jefferies Releases a Buy Rating on Viridian Therapeutics (VRDN)
Jefferies Initiates Viridian Therapeutics(VRDN.US) With Buy Rating, Announces Target Price $45
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $38 to $61
Viridian Therapeutics Price Target Maintained With a $38.00/Share by Needham
Viridian Therapeutics Earns Buy Rating on Promising Trial Results and Strong Financial Position
LifeSci Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $46
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $44
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Viridian Therapeutics (VRDN) and Select Medical (SEM)
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $45
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31
Viridian Therapeutics Analyst Ratings
Needham Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $45